Coordinated Financial Services Inc. Purchases New Stake in Eli Lilly and Company (NYSE:LLY)

Coordinated Financial Services Inc. acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, Holdings Channel reports. The firm acquired 275 shares of the company’s stock, valued at approximately $212,000.

Several other large investors have also recently added to or reduced their stakes in the company. United Community Bank increased its position in Eli Lilly and Company by 11.1% during the 4th quarter. United Community Bank now owns 1,197 shares of the company’s stock worth $924,000 after buying an additional 120 shares during the period. Personal CFO Solutions LLC increased its position in Eli Lilly and Company by 20.5% during the 4th quarter. Personal CFO Solutions LLC now owns 3,302 shares of the company’s stock worth $2,549,000 after buying an additional 562 shares during the period. Barings LLC grew its holdings in shares of Eli Lilly and Company by 251.4% during the 4th quarter. Barings LLC now owns 1,669 shares of the company’s stock worth $1,288,000 after purchasing an additional 1,194 shares in the last quarter. Dorsey & Whitney Trust CO LLC grew its holdings in shares of Eli Lilly and Company by 18.0% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 49,602 shares of the company’s stock worth $38,293,000 after purchasing an additional 7,562 shares in the last quarter. Finally, Naviter Wealth LLC grew its holdings in shares of Eli Lilly and Company by 82.4% during the 4th quarter. Naviter Wealth LLC now owns 10,019 shares of the company’s stock worth $7,734,000 after purchasing an additional 4,525 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of several analyst reports. Truist Financial increased their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a research note on Friday, January 17th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research note on Thursday, January 16th. Finally, Citigroup cut their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,007.50.

Eli Lilly and Company Trading Down 4.8 %

Shares of Eli Lilly and Company stock opened at $868.59 on Monday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 52 week low of $711.40 and a 52 week high of $972.53. The stock has a 50 day moving average price of $826.63 and a two-hundred day moving average price of $847.24. The stock has a market capitalization of $823.57 billion, a PE ratio of 74.17, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has initiated a stock buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.